Gastroenterology

Investigators articulated the development and validation of an enzyme-linked immunoassay against hepatitis C virus (HCV). They suggest the implementation of this low cost assay among at-risk populations.

The increase does not appear to have a negative impact on post transplant survival, investigators say.

There are several early phase trials underway for new hepatitis B virus treatments.

The goal for many is to eradicate HCV by the year 2030.

The only adverse event identified was mild nausea for a duration of 10-21 days.

Dr. Sanyal talks about the importance in having ongoing real-world data for NAFLD and NASH.

Washington DC, Hawaii, Oklahoma, California, Tennessee, West Virginia, Mississippi, Oregon, Washington, Louisiana, Kentucky, and New York all had HBV-related mortality rates higher than the national average.

Tenofovir was linked to a decreased incidence rate of HCC compared to entecavir. However, this difference was not considered statistically significant.

Dr. Remo Panaccione speaks on promising long-term data of ustekinumab for Crohn's disease and ulcerative colitis, and how it could function as either a first-line treatment or alternative option for patients who were previously exposed biologic therapies.

Between 2015-2019 the number of HBV-related deaths increased by 2.9%.

Smoking was not linked to colonic transit times and colonic transit was not associated with IBS symptom severity.

C1M, C3M, and C4M were significantly reduced in patients with structuring disease.

Prematurity was also linked to infant regurgitation, infant colic, infant dysphasia, and functional constipation.

For pediatric patients, the anti-HBs (+) rates were relatively stable at approximately 60%, but the anti-HBc (+) rates increased significantly with age.

The investigators found pharmacotherapy for AUD was associated with a lower incidence of hepatic decompensation in patients with cirrhosis.

There was a greater proportion of the undetected (19%) or previously detected (23%) dysplasia group that had concurrent primary sclerosing cholangitis compared to only 3% of the group without dysplasia.

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

Interventions could be utilized in patients awaiting liver transplantations to avoid further complications or mortality.

ALT can be used a marker for NAFLD severity in pediatric patients.

The prevalence of NAFLD in the pediatric population has increased in recent years.

April 6 is Donate Life Living Donor Day, a day to promote liver donations.

The guidelines focus on diagnosing and screening for Barrett’s esophagus and esophageal adenocarcinoma.

Patients with irritable bowel syndrome more frequently self-reported non-celiac gluten sensitivity compared to the control group, as well as major gastrointestinal symptoms found in the study included bloating, abdominal discomfort, and belching.

The guidelines replace risk-based reccomendations for adults between 19-59 years.

Investigators were uncertain as to whether low fecal Alistipes could be used as a marker for predicting the outcome of FMT.